Opioid crisis sparks leadership changes at Purdue Pharma

In an attempt to distance itself from the opioid epedemic, Purdue Pharma recently made some leadership changes to its board of directors and executive committee, as it battles hundreds of lawsuits across the United States concerning opioid-related deceptive sales and marketing practices that are the focus of U.S. enforcement authorities.

THIS IS MEMBERS-ONLY CONTENT

SINGLE MEMBERSHIP                                             CORPORATE MEMBERSHIP

You are not logged in and do not have access to members-only content.

If you are already a registered user or a member, SIGN IN now.